CFRD mortality has significantly decreasedover time, and the gap in mortalitybetween cystic fibrosis patients withand without diabetes has considerablynarrowed (92). There are limited clinicaltrial data on therapy for CFRD. The largeststudy compared three regimens: premealinsulin aspart, repaglinide, or oral placeboin cystic fibrosis patients with diabetes orabnormal glucose tolerance. Participantsall had weight loss in the year precedingtreatment; however, in the insulintreatedgroup, this pattern was reversed,and patients gained 0.39 (6 0.21) BMIunits (P 5 0.02). The repaglinide-treatedgroup had initial weight gain, but this wasnot sustained by 6 months. The placebogroup continued to lose weight (93).Insulin remains the most widely usedtherapy for CFRD (94).